{"id":75711,"date":"2026-09-30T19:41:46","date_gmt":"2026-09-30T19:41:46","guid":{"rendered":"https:\/\/www.stocktargetadvisor.com\/blog\/?p=75711"},"modified":"2026-09-30T19:43:23","modified_gmt":"2026-09-30T19:43:23","slug":"u-s-analyst-updates-september-30th-2026","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/","title":{"rendered":"U.S. Analyst Updates: September 30th, 2026"},"content":{"rendered":"

Analyst Ratings (USA)<\/a><\/h2>\n

Today\u2019s U.S. analyst updates suggest a selective and cautious market outlook, with optimism concentrated in cloud computing, AI infrastructure and networking, although target cuts across parts of enterprise software show continued valuation scrutiny. Financials face a more restrained outlook, with several bank and lending downgrades, while industrials, aerospace and chemicals saw numerous target reductions despite many favourable ratings remaining intact. Consumer sentiment is mixed: retail upgrades contrast with reductions in travel, restaurants and packaged foods. Energy remains selective, with stronger targets for refining and some producers offset by weaker oilfield-service forecasts. Utilities generally experienced lower targets, while healthcare and biotechnology showed a combination of positive coverage initiations and company-specific downgrades. Overall, the updates point to continued confidence in selected growth opportunities, accompanied by tighter expectations for valuations and earnings across much of the broader market.<\/p>\n

U.S. Analyst Updates (238)<\/h3>\n

3M (MMM)<\/strong> \u2014 Deutsche Bank maintained its Hold rating and raised its price target to US$194.00 from US$192.00.<\/p>\n

Accelerant (ARX)<\/strong> \u2014 TD Cowen downgraded the stock to Hold from Buy, lowering its price target to US$20.25 from US$30.00.<\/p>\n

Accenture (ACN)<\/strong> \u2014 UBS reiterated its Buy rating.<\/p>\n

Achieve Life Sciences (ACHV)<\/strong> \u2014 Stifel Nicolaus initiated coverage with a Buy rating and a US$18 price target.<\/p>\n

Akamai Technologies (AKAM)<\/strong> \u2014 President Capital maintained its Buy rating and raised its price target to US$168.00 from US$150.00.<\/p>\n

Aldeyra Therapeutics (ALDX)<\/strong> \u2014 H.C. Wainwright reiterated its Neutral rating with a US$2.00 price target.<\/p>\n

Ally Financial (ALLY)<\/strong> \u2014 Wells Fargo downgraded the stock to Equal Weight from Overweight, lowering its price target to US$42.00 from US$55.00.<\/p>\n

Alnylam Pharmaceuticals (ALNY)<\/strong> \u2014 Cantor Fitzgerald reiterated its Neutral rating.<\/p>\n

Alnylam Pharmaceuticals (ALNY)<\/strong> \u2014 JPMorgan Chase maintained its Overweight rating and lowered its price target to US$369.00 from US$375.00.<\/p>\n

Amazon.com (AMZN)<\/strong> \u2014 Rosenblatt Securities maintained its Buy rating and raised its price target to US$360.00 from US$335.00.<\/p>\n

Ameren (AEE)<\/strong> \u2014 Mizuho maintained its Outperform rating and lowered its price target to US$113.00 from US$124.00.<\/p>\n

American Electric Power (AEP)<\/strong> \u2014 Scotiabank maintained its Sector Perform rating and lowered its price target to US$131.00 from US$140.00.<\/p>\n

American Express (AXP)<\/strong> \u2014 Citigroup maintained its Neutral rating and lowered its price target to US$340.00 from US$355.00.<\/p>\n

American Tower (AMT)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$199.00 from US$198.00.<\/p>\n

Amphenol (APH)<\/strong> \u2014 Wolfe Research initiated coverage with an Outperform rating and a US$105.00 price target.<\/p>\n

Amplitude (AMPL)<\/strong> \u2014 Piper Sandler maintained its Overweight rating and raised its price target to US$18.00 from US$13.00.<\/p>\n

AnaptysBio (ANAB)<\/strong> \u2014 JPMorgan Chase maintained its Overweight rating and lowered its price target to US$60.00 from US$70.00.<\/p>\n

Annexon (ANNX)<\/strong> \u2014 JPMorgan Chase maintained its Overweight rating and raised its price target to US$15.00 from US$14.00.<\/p>\n

Arcus Biosciences (RCUS)<\/strong> \u2014 Wedbush reiterated its Outperform rating with a US$43.00 price target.<\/p>\n

Arista Networks (ANET)<\/strong> \u2014 Bernstein initiated coverage with an Outperform rating and a US$250.00 price target.<\/p>\n

ASML (ASML)<\/strong> \u2014 Jefferies reiterated its Neutral rating.<\/p>\n

ATI (ATI)<\/strong> \u2014 Wells Fargo maintained its Overweight rating and lowered its price target to US$240.00 from US$275.00.<\/p>\n

Baker Hughes (BKR)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$69.00 from US$72.00.<\/p>\n

Ballard Power Systems (BLDP)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$2.15 from US$6.50.<\/p>\n

Banc of California (BANC)<\/strong> \u2014 Wells Fargo maintained its Overweight rating and lowered its price target to US$22.00 from US$23.00.<\/p>\n

Bank of N.T. Butterfield & Son (NTB)<\/strong> \u2014 Wells Fargo maintained its Equal Weight rating and raised its price target to US$65.00 from US$61.00.<\/p>\n

BankUnited (BKU)<\/strong> \u2014 Wells Fargo downgraded the stock to Equal Weight from Overweight, with a US$47 price target.<\/p>\n

BioCryst Pharmaceuticals (BCRX)<\/strong> \u2014 JPMorgan Chase maintained its Neutral rating and raised its price target to US$13.00 from US$12.00.<\/p>\n

Biomea Fusion (BMEA)<\/strong> \u2014 Citigroup reiterated its Market Outperform rating.<\/p>\n

BlossomHill Therapeutics (BLSM)<\/strong> \u2014 H.C. Wainwright reiterated its Buy rating.<\/p>\n

Boeing (BA)<\/strong> \u2014 Bernstein reiterated its Outperform rating.<\/p>\n

Boeing (BA)<\/strong> \u2014 William Blair reiterated its Outperform rating.<\/p>\n

BOK Financial (BOKF)<\/strong> \u2014 Wells Fargo downgraded the stock to Underweight from Equal Weight, with a US$135 price target.<\/p>\n

Booking Holdings (BKNG)<\/strong> \u2014 Truist Securities maintained its Buy rating and lowered its price target to US$216.00 from US$242.00.<\/p>\n

Braze (BRZE)<\/strong> \u2014 Cantor Fitzgerald reiterated its Overweight rating with a US$38.00 price target.<\/p>\n

BWX Technologies (BWXT)<\/strong> \u2014 BofA Securities maintained its Buy rating and lowered its price target to US$210.00 from US$250.00.<\/p>\n

BWX Technologies (BWXT)<\/strong> \u2014 BTIG Research reiterated its Buy rating with a US$235.00 price target.<\/p>\n

BWX Technologies (BWXT)<\/strong> \u2014 Citigroup reiterated its Outperform rating.<\/p>\n

BWX Technologies (BWXT)<\/strong> \u2014 Guggenheim reiterated its Buy rating with a US$192.00 price target.<\/p>\n

BWX Technologies (BWXT)<\/strong> \u2014 Northland Securities maintained its Outperform rating and lowered its price target to US$220.00 from US$250.00.<\/p>\n

Cactus (WHD)<\/strong> \u2014 Citigroup reiterated its Neutral rating.<\/p>\n

CarMax (KMX)<\/strong> \u2014 Baird maintained its Outperform rating and raised its price target to US$70.00 from US$64.00.<\/p>\n

CarMax (KMX)<\/strong> \u2014 Barclays set its price target to US$67.00.<\/p>\n

CarMax (KMX)<\/strong> \u2014 BNP Paribas Exane maintained its Underperform rating and raised its price target to US$48.00 from US$33.00.<\/p>\n

CarMax (KMX)<\/strong> \u2014 BofA Securities maintained its Underperform rating and raised its price target to US$50.00 from US$45.00.<\/p>\n

CarMax (KMX)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and raised its price target to US$53.00 from US$47.00.<\/p>\n

CarMax (KMX)<\/strong> \u2014 RBC Capital maintained its Sector Perform rating and raised its price target to US$56.00 from US$45.00.<\/p>\n

CarMax (KMX)<\/strong> \u2014 Truist Securities maintained its Hold rating and raised its price target to US$60.00 from US$50.00.<\/p>\n

CarMax (KMX)<\/strong> \u2014 UBS maintained its Neutral rating and raised its price target to US$62.00 from US$57.00.<\/p>\n

Carnival (CCL)<\/strong> \u2014 Bernstein reiterated its Market Perform rating with a US$28.70 price target.<\/p>\n

Carnival (CCL)<\/strong> \u2014 BNP Paribas Exane maintained its Outperform rating and lowered its price target to US$31.00 from US$33.00.<\/p>\n

Carnival (CCL)<\/strong> \u2014 Mizuho maintained its Outperform rating and lowered its price target to US$38.00 from US$39.00.<\/p>\n

Carnival (CCL)<\/strong> \u2014 Susquehanna maintained its Positive rating and lowered its price target to US$28.00 from US$33.00.<\/p>\n

Carnival (CCL)<\/strong> \u2014 UBS reiterated its Buy rating with a US$36.00 price target.<\/p>\n

Carpenter Technology (CRS)<\/strong> \u2014 Wells Fargo maintained its Equal Weight rating and lowered its price target to US$430.00 from US$540.00.<\/p>\n

Carrier Global (CARR)<\/strong> \u2014 Deutsche Bank maintained its Hold rating and lowered its price target to US$64.00 from US$71.00.<\/p>\n

Carrier Global (CARR)<\/strong> \u2014 Goldman Sachs maintained its Buy rating and lowered its price target to US$74.00 from US$85.00.<\/p>\n

Cartesian Therapeutics (RNAC)<\/strong> \u2014 H.C. Wainwright reiterated its Buy rating with a US$25.00 price target.<\/p>\n

Carvana (CVNA)<\/strong> \u2014 Oppenheimer maintained its Outperform rating and adjusted its price target to US$90.00 from US$450.00 following the stock split.<\/p>\n

Cavco Industries (CVCO)<\/strong> \u2014 Oppenheimer initiated coverage with an Outperform rating and a US$720.00 price target.<\/p>\n

Celanese (CE)<\/strong> \u2014 Citigroup maintained its Buy rating and lowered its price target to US$58.00 from US$60.00.<\/p>\n

Celcuity (CELC)<\/strong> \u2014 Needham maintained its Buy rating and lowered its price target to US$134.00 from US$140.00.<\/p>\n

Celestica (CLS)<\/strong> \u2014 Bernstein initiated coverage with an Outperform rating and a US$520.00 price target.<\/p>\n

Certara (CERT)<\/strong> \u2014 UBS resumed coverage with a Neutral rating and a US$10.00 price target.<\/p>\n

Champion Homes (SKY)<\/strong> \u2014 Oppenheimer initiated coverage with a Perform rating.<\/p>\n

Charles River Laboratories International (CRL)<\/strong> \u2014 UBS resumed coverage with a Buy rating and a US$357.00 price target.<\/p>\n

Chemours (CC)<\/strong> \u2014 Mizuho maintained its Outperform rating and lowered its price target to US$18.00 from US$20.00.<\/p>\n

Chesapeake Utilities (CPK)<\/strong> \u2014 Wells Fargo maintained its Equal Weight rating and raised its price target to US$136.00 from US$134.00.<\/p>\n

Ciena (CIEN)<\/strong> \u2014 Bernstein initiated coverage with an Outperform rating and a US$440.00 price target.<\/p>\n

Cintas (CTAS)<\/strong> \u2014 Citigroup maintained its Sell rating and raised its price target to US$181.00 from US$180.00.<\/p>\n

Cisco Systems (CSCO)<\/strong> \u2014 Bernstein initiated coverage with a Market Perform rating and a US$110.00 price target.<\/p>\n

Coherent (COHR)<\/strong> \u2014 Bernstein initiated coverage with an Outperform rating and a US$350 price target.<\/p>\n

Columbia Banking System (COLB)<\/strong> \u2014 Wells Fargo maintained its Equal Weight rating and lowered its price target to US$32.00 from US$34.00.<\/p>\n

Concentrix (CNXC)<\/strong> \u2014 Canaccord Genuity reiterated its Buy rating with a US$45.00 price target.<\/p>\n

Connect Biopharma (CNTB)<\/strong> \u2014 BTIG Research maintained its Buy rating and lowered its price target to US$5.00.<\/p>\n

CoreWeave (CRWV)<\/strong> \u2014 William Blair initiated coverage with an Outperform rating.<\/p>\n

Corning (GLW)<\/strong> \u2014 Bernstein initiated coverage with a Market Perform rating and a US$140.00 price target.<\/p>\n

Crown Castle (CCI)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$86.00 from US$84.00.<\/p>\n

Cummins (CMI)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$741.00 from US$835.00.<\/p>\n

Dakota Gold (DC)<\/strong> \u2014 H.C. Wainwright reiterated its Buy rating with a US$10.75 price target.<\/p>\n

DBV Technologies (DBVT)<\/strong> \u2014 Citigroup reiterated its Market Outperform rating.<\/p>\n

DICK’S Sporting Goods (DKS)<\/strong> \u2014 Guggenheim reiterated its Neutral rating.<\/p>\n

DocGo (DCGO)<\/strong> \u2014 Needham reiterated its Buy rating.<\/p>\n

DoorDash (DASH)<\/strong> \u2014 Citigroup reiterated its Market Outperform rating.<\/p>\n

Dow (DOW)<\/strong> \u2014 Citigroup downgraded the stock to Neutral from Buy, with a US$30 price target.<\/p>\n

Duke Energy (DUK)<\/strong> \u2014 Scotiabank lowered its price target to US$131.00 from US$146.00.<\/p>\n

DuPont de Nemours (DD)<\/strong> \u2014 Goldman Sachs maintained its Neutral rating and lowered its price target to US$153.00 from US$159.00.<\/p>\n

Dutch Bros (BROS)<\/strong> \u2014 Oppenheimer maintained its Outperform rating and lowered its price target to US$66.00 from US$82.00.<\/p>\n

Dyne Therapeutics (DYN)<\/strong> \u2014 Cantor Fitzgerald reiterated its Buy rating.<\/p>\n

Dyne Therapeutics (DYN)<\/strong> \u2014 Chardan Capital reiterated its Buy rating with a US$38.00 price target.<\/p>\n

Dyne Therapeutics (DYN)<\/strong> \u2014 H.C. Wainwright maintained its Buy rating and lowered its price target to US$32.00 from US$50.00.<\/p>\n

Dyne Therapeutics (DYN)<\/strong> \u2014 Jefferies reiterated its Buy rating with a US$50.00 price target.<\/p>\n

Eastman Chemical (EMN)<\/strong> \u2014 Citigroup maintained its Buy rating and lowered its price target to US$76.00 from US$81.00.<\/p>\n

Elanco Animal Health (ELAN)<\/strong> \u2014 KeyBanc Capital Markets reiterated its Overweight rating.<\/p>\n

Emerson Electric (EMR)<\/strong> \u2014 Deutsche Bank maintained its Hold rating and raised its price target to US$174.00 from US$169.00.<\/p>\n

Equifax (EFX)<\/strong> \u2014 BMO Capital Markets maintained its Market Perform rating and lowered its price target to US$160.00 from US$179.00.<\/p>\n

Expedia Group (EXPE)<\/strong> \u2014 Truist Securities maintained its Hold rating and lowered its price target to US$288.00 from US$309.00.<\/p>\n

Expeditors International of Washington (EXPD)<\/strong> \u2014 BNP Paribas Exane initiated coverage with a Neutral rating and a US$180.00 price target.<\/p>\n

Fair Isaac (FICO)<\/strong> \u2014 Barclays maintained its Overweight rating and lowered its price target to US$935.00 from US$1,700.00.<\/p>\n

Fair Isaac (FICO)<\/strong> \u2014 BMO Capital Markets maintained its Outperform rating and lowered its price target to US$1,150.00 from US$1,550.00.<\/p>\n

Fair Isaac (FICO)<\/strong> \u2014 BofA Securities downgraded the stock to Neutral from Buy, lowering its price target to US$700.00 from US$1,400.00.<\/p>\n

Fair Isaac (FICO)<\/strong> \u2014 Susquehanna set its price target to US$700.00.<\/p>\n

Fair Isaac (FICO)<\/strong> \u2014 Wells Fargo maintained its Overweight rating and lowered its price target to US$950.00 from US$1,350.00.<\/p>\n

FedEx (FDX)<\/strong> \u2014 BNP Paribas Exane maintained its Neutral rating and raised its price target to US$300.00 from US$269.80.<\/p>\n

Ferrari (RACE)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and lowered its price target to US$456.00 from US$460.00.<\/p>\n

First Hawaiian (FHB)<\/strong> \u2014 Wells Fargo maintained its Underweight rating and lowered its price target to US$26.00 from US$28.00.<\/p>\n

First Horizon (FHN)<\/strong> \u2014 Wells Fargo maintained its Equal Weight rating and lowered its price target to US$25.00 from US$28.00.<\/p>\n

First Solar (FSLR)<\/strong> \u2014 Piper Sandler maintained its Overweight rating and lowered its price target to US$251.00 from US$260.00.<\/p>\n

First Tracks Biotherapeutics (TRAX)<\/strong> \u2014 Canaccord Genuity initiated coverage with a Buy rating and a US$50.00 price target.<\/p>\n

Flywire (FLYW)<\/strong> \u2014 RBC Capital reiterated its Outperform rating with a US$25.00 price target.<\/p>\n

Forbright (FRBT)<\/strong> \u2014 Wells Fargo maintained its Overweight rating and lowered its price target to US$21.00 from US$22.00.<\/p>\n

FormFactor (FORM)<\/strong> \u2014 Deutsche Bank initiated coverage with a Buy rating and a US$200.00 price target.<\/p>\n

Fortrea (FTRE)<\/strong> \u2014 UBS initiated coverage with a Neutral rating and a US$22.00 price target.<\/p>\n

GE Aerospace (GE)<\/strong> \u2014 Wells Fargo maintained its Overweight rating and lowered its price target to US$380.00 from US$390.00.<\/p>\n

Generac (GNRC)<\/strong> \u2014 Citigroup reiterated its Neutral rating.<\/p>\n

Generac (GNRC)<\/strong> \u2014 Stifel Nicolaus maintained its Buy rating and raised its price target to US$290.00 from US$285.00.<\/p>\n

Global Business Travel Group (GBTG)<\/strong> \u2014 BTIG Research reiterated its Neutral rating.<\/p>\n

Graphic Packaging (GPK)<\/strong> \u2014 RBC Capital maintained its Sector Perform rating and lowered its price target to US$10.00 from US$11.00.<\/p>\n

Grocery Outlet (GO)<\/strong> \u2014 BofA Securities upgraded the stock to Buy from Neutral, raising its price target to US$15.00 from US$12.50.<\/p>\n

H2O America (HTO)<\/strong> \u2014 Barclays maintained its Overweight rating and lowered its price target to US$66.00 from US$67.00.<\/p>\n

Hawaiian Electric Industries (HE)<\/strong> \u2014 Barclays maintained its Equal Weight rating and lowered its price target to US$9.00 from US$12.00.<\/p>\n

HawkEye 360 (HAWK)<\/strong> \u2014 RBC Capital maintained its Outperform rating and lowered its price target to US$28.00 from US$33.00.<\/p>\n

HEICO (HEI)<\/strong> \u2014 Wells Fargo maintained its Equal Weight rating and lowered its price target to US$335.00 from US$350.00.<\/p>\n

Hexcel (HXL)<\/strong> \u2014 Wells Fargo maintained its Overweight rating and lowered its price target to US$105.00 from US$120.00.<\/p>\n

Hinge Health (HNGE)<\/strong> \u2014 Needham maintained its Buy rating and raised its price target to US$115.00 from US$97.00.<\/p>\n

Howmet Aerospace (HWM)<\/strong> \u2014 Citigroup reiterated its Buy rating.<\/p>\n

Howmet Aerospace (HWM)<\/strong> \u2014 Wells Fargo maintained its Equal Weight rating and lowered its price target to US$255.00 from US$315.00.<\/p>\n

Huntsman (HUN)<\/strong> \u2014 Citigroup maintained its Neutral rating and lowered its price target to US$9.00 from US$11.00.<\/p>\n

ICON plc (ICLR)<\/strong> \u2014 UBS resumed coverage with a Neutral rating and a US$195.00 price target.<\/p>\n

Illinois Tool Works (ITW)<\/strong> \u2014 Deutsche Bank maintained its Hold rating and lowered its price target to US$281.00 from US$287.00.<\/p>\n

Immix Biopharma (IMMX)<\/strong> \u2014 Citigroup reiterated its Market Outperform rating.<\/p>\n

Innio (INIO)<\/strong> \u2014 Goldman Sachs set its price target to US$35.00.<\/p>\n

Insmed (INSM)<\/strong> \u2014 Barclays maintained its Overweight rating and lowered its price target to US$207.00 from US$237.00.<\/p>\n

Iovance Biotherapeutics (IOVA)<\/strong> \u2014 Wells Fargo maintained its Overweight rating and raised its price target to US$18.00 from US$14.00.<\/p>\n

IperionX (IPX)<\/strong> \u2014 B. Riley Securities maintained its Buy rating and lowered its price target to US$34.00 from US$52.00.<\/p>\n

IQVIA (IQV)<\/strong> \u2014 UBS resumed coverage with a Buy rating and a US$345.00 price target.<\/p>\n

Jack Henry & Associates (JKHY)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and lowered its price target to US$158.00 from US$170.00.<\/p>\n

Jack Henry & Associates (JKHY)<\/strong> \u2014 RBC Capital reiterated its Outperform rating with a US$178.00 price target.<\/p>\n

Jazz Pharmaceuticals (JAZZ)<\/strong> \u2014 Citigroup initiated coverage with a Buy rating and a US$325.00 price target.<\/p>\n

John B. Sanfilippo & Son (JBSS)<\/strong> \u2014 BWS Financial reiterated its Buy rating with a US$109.00 price target.<\/p>\n

Johnson Controls International (JCI)<\/strong> \u2014 Deutsche Bank maintained its Buy rating and lowered its price target to US$178.00 from US$180.00.<\/p>\n

Johnson Controls International (JCI)<\/strong> \u2014 Goldman Sachs maintained its Buy rating and raised its price target to US$191.00 from US$186.00.<\/p>\n

Kiniksa Pharmaceuticals International (KNSA)<\/strong> \u2014 Wells Fargo initiated coverage with an Overweight rating and a US$87.00 price target.<\/p>\n

Kodiak Sciences (KOD)<\/strong> \u2014 Goldman Sachs reiterated its Neutral rating with a US$103.00 price target.<\/p>\n

Lamb Weston (LW)<\/strong> \u2014 JPMorgan Chase maintained its Neutral rating and lowered its price target to US$46.00 from US$52.00.<\/p>\n

Levi Strauss & Co. (LEVI)<\/strong> \u2014 BTIG Research reiterated its Buy rating with a US$27.00 price target.<\/p>\n

Liberty Energy (LBRT)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$31.00 from US$35.00.<\/p>\n

Lumentum (LITE)<\/strong> \u2014 Bernstein initiated coverage with an Outperform rating and a US$1,220.00 price target.<\/p>\n

LyondellBasell Industries (LYB)<\/strong> \u2014 Citigroup downgraded the stock to Neutral from Buy, lowering its price target to US$63.00 from US$72.00.<\/p>\n

Medpace (MEDP)<\/strong> \u2014 UBS resumed coverage with a Neutral rating and a US$673.00 price target.<\/p>\n

Medtronic (MDT)<\/strong> \u2014 TD Cowen reiterated its Buy rating with a US$110.00 price target.<\/p>\n

Microsoft (MSFT)<\/strong> \u2014 Piper Sandler maintained its Overweight rating and raised its price target to US$610.00 from US$550.00.<\/p>\n

Mobileye Global (MBLY)<\/strong> \u2014 Barclays downgraded the stock to Equal Weight from Overweight, lowering its price target to US$9.00 from US$14.00.<\/p>\n

Moderna (MRNA)<\/strong> \u2014 Citigroup downgraded the stock to Sell from Neutral, raising its price target to US$80.00 from US$60.00.<\/p>\n

MongoDB (MDB)<\/strong> \u2014 BMO Capital Markets maintained its Outperform rating and lowered its price target to US$420.00 from US$450.00.<\/p>\n

MongoDB (MDB)<\/strong> \u2014 Citizens JMP reiterated its Market Outperform rating with a US$519.00 price target.<\/p>\n

MongoDB (MDB)<\/strong> \u2014 Morgan Stanley reiterated its Overweight rating.<\/p>\n

MongoDB (MDB)<\/strong> \u2014 Needham reiterated its Buy rating with a US$430.00 price target.<\/p>\n

MongoDB (MDB)<\/strong> \u2014 Piper Sandler reiterated its Overweight rating with a US$470.00 price target.<\/p>\n

MongoDB (MDB)<\/strong> \u2014 RBC Capital reiterated its Outperform rating with a US$465.00 price target.<\/p>\n

MongoDB (MDB)<\/strong> \u2014 Stephens maintained its Equal Weight rating and lowered its price target to US$372.00 from US$398.00.<\/p>\n

MongoDB (MDB)<\/strong> \u2014 Stifel Nicolaus maintained its Buy rating and lowered its price target to US$385.00 from US$465.00.<\/p>\n

MongoDB (MDB)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$375.00 from US$410.00.<\/p>\n

Morgan Stanley (MS)<\/strong> \u2014 Citigroup reiterated its Neutral rating.<\/p>\n

National Energy Services Reunited (NESR)<\/strong> \u2014 Capital One initiated coverage with an Overweight rating and a US$44.00 price target.<\/p>\n

National Energy Services Reunited (NESR)<\/strong> \u2014 National Bank Financial set its price target to US$44.00.<\/p>\n

Nebius Group (NBIS)<\/strong> \u2014 William Blair initiated coverage with an Outperform rating.<\/p>\n

Neogen (NEOG)<\/strong> \u2014 Guggenheim maintained its Buy rating and raised its price target to US$14.00 from US$12.00.<\/p>\n

NetApp (NTAP)<\/strong> \u2014 BofA Securities maintained its Neutral rating and raised its price target to US$220.00 from US$200.00.<\/p>\n

NextEra Energy (NEE)<\/strong> \u2014 Scotiabank maintained its Outperform rating and lowered its price target to US$99.00 from US$110.00.<\/p>\n

Nextpower (NXT)<\/strong> \u2014 Piper Sandler maintained its Overweight rating and lowered its price target to US$110.00 from US$116.00.<\/p>\n

NICE (NICE)<\/strong> \u2014 Oppenheimer upgraded the stock to Outperform from Perform, with a US$150.00 price target.<\/p>\n

Norfolk Southern (NSC)<\/strong> \u2014 Evercore raised its price target to US$360.00 from US$358.00.<\/p>\n

Nuvation Bio (NUVB)<\/strong> \u2014 Citigroup initiated coverage with a Buy rating and a US$12.00 price target.<\/p>\n

Olin (OLN)<\/strong> \u2014 Citigroup maintained its Neutral rating and lowered its price target to US$17.00 from US$19.00.<\/p>\n

Olin (OLN)<\/strong> \u2014 Goldman Sachs set its price target to US$18.00.<\/p>\n

Ovintiv (OVV)<\/strong> \u2014 National Bank Financial maintained its Outperform rating and raised its price target to US$91.00 from US$83.00.<\/p>\n

Pasqal Holding (PSQL)<\/strong> \u2014 Needham initiated coverage with a Buy rating and a US$16.00 price target.<\/p>\n

Pasqal Holding (PSQL)<\/strong> \u2014 Williams Trading set its price target to US$16.00.<\/p>\n

Paysign (PAYS)<\/strong> \u2014 DA Davidson maintained its Buy rating and raised its price target to US$15.00 from US$12.00.<\/p>\n

PepsiCo (PEP)<\/strong> \u2014 Barclays lowered its price target to US$133.00 from US$142.00.<\/p>\n

PepsiCo (PEP)<\/strong> \u2014 Evercore lowered its price target to US$135.00 from US$150.00.<\/p>\n

Perpetua Resources (PPTA)<\/strong> \u2014 H.C. Wainwright reiterated its Buy rating with a US$43.50 price target.<\/p>\n

Phillips 66 (PSX)<\/strong> \u2014 Goldman Sachs maintained its Neutral rating and raised its price target to US$274.00 from US$245.00.<\/p>\n

Phillips 66 (PSX)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$295.00 from US$255.00.<\/p>\n

Pinnacle Financial Partners (PNFP)<\/strong> \u2014 Wells Fargo upgraded the stock to Overweight from Equal Weight, with a US$118.00 price target.<\/p>\n

Portland General Electric (POR)<\/strong> \u2014 BMO Capital Markets maintained its Market Perform rating and lowered its price target to US$47.00 from US$52.00.<\/p>\n

PPG Industries (PPG)<\/strong> \u2014 Citigroup maintained its Neutral rating and lowered its price target to US$118.00 from US$121.00.<\/p>\n

Procter & Gamble (PG)<\/strong> \u2014 TD Cowen reiterated its Hold rating with a US$150.00 price target.<\/p>\n

Progyny (PGNY)<\/strong> \u2014 Wells Fargo initiated coverage with an Overweight rating and a US$37.00 price target.<\/p>\n

QumulusAI (QMLS)<\/strong> \u2014 Chardan Capital reiterated its Buy rating with a US$23.00 price target.<\/p>\n

Regal Rexnord (RRX)<\/strong> \u2014 Goldman Sachs set its price target to US$216.00.<\/p>\n

Rexford Industrial Realty (REXR)<\/strong> \u2014 Cantor Fitzgerald reiterated its Overweight rating.<\/p>\n

Rezolute (RZLT)<\/strong> \u2014 Lake Street Capital initiated coverage with a Buy rating and a US$9.00 price target.<\/p>\n

Robinhood Markets (HOOD)<\/strong> \u2014 Morgan Stanley reiterated its Overweight rating with a US$150.00 price target.<\/p>\n

Rockwell Automation (ROK)<\/strong> \u2014 Deutsche Bank maintained its Hold rating and raised its price target to US$500.00 from US$469.00.<\/p>\n

Rockwell Automation (ROK)<\/strong> \u2014 Goldman Sachs maintained its Neutral rating and lowered its price target to US$485.00 from US$510.00.<\/p>\n

Sable Offshore (SOC)<\/strong> \u2014 Roth Capital maintained its Buy rating and lowered its price target to US$10.00 from US$11.00.<\/p>\n

Sarepta Therapeutics (SRPT)<\/strong> \u2014 JPMorgan Chase maintained its Neutral rating and lowered its price target to US$20.00 from US$23.00.<\/p>\n

SBA Communications (SBAC)<\/strong> \u2014 Barclays maintained its Overweight rating and lowered its price target to US$207.00 from US$208.00.<\/p>\n

Select Water Solutions (WTTR)<\/strong> \u2014 BofA Securities maintained its Buy rating and raised its price target to US$28.00 from US$24.00.<\/p>\n

Select Water Solutions (WTTR)<\/strong> \u2014 UBS reiterated its Buy rating with a US$28.00 price target.<\/p>\n

Sensient Technologies (SXT)<\/strong> \u2014 UBS maintained its Buy rating and raised its price target to US$157.00 from US$155.00.<\/p>\n

Smithfield Foods (SFD)<\/strong> \u2014 Stephens initiated coverage with an Equal Weight rating and a US$22.00 price target.<\/p>\n

Solstice Advanced Materials (SOLS)<\/strong> \u2014 RBC Capital reiterated its Outperform rating with a US$82.00 price target.<\/p>\n

SoundThinking (SSTI)<\/strong> \u2014 Citigroup reiterated its Market Perform rating.<\/p>\n

SoundThinking (SSTI)<\/strong> \u2014 Jefferies set its price target to US$9.00.<\/p>\n

SoundThinking (SSTI)<\/strong> \u2014 Roth Capital downgraded the stock to Neutral from Buy, with a US$9.00 price target.<\/p>\n

SpaceX (SPCX)<\/strong> \u2014 Needham reiterated its Buy rating.<\/p>\n

Sterling Infrastructure (STRL)<\/strong> \u2014 Cantor Fitzgerald reiterated its Overweight rating with a US$742.00 price target.<\/p>\n

Stryker (SYK)<\/strong> \u2014 Stifel Nicolaus maintained its Buy rating and lowered its price target to US$330.00 from US$360.00.<\/p>\n

Summit Therapeutics (SMMT)<\/strong> \u2014 H.C. Wainwright reiterated its Neutral rating.<\/p>\n

Surgery Partners (SGRY)<\/strong> \u2014 RBC Capital reiterated its Outperform rating with a US$19.00 price target.<\/p>\n

Sutro Biopharma (STRO)<\/strong> \u2014 Wells Fargo resumed coverage with an Overweight rating and a US$49.00 price target.<\/p>\n

Tandem Diabetes Care (TNDM)<\/strong> \u2014 Citigroup maintained its Neutral rating and lowered its price target to US$20.00 from US$24.00.<\/p>\n

Target (TGT)<\/strong> \u2014 HSBC Securities upgraded the stock to Buy from Hold, with a US$190 price target.<\/p>\n

Tectonic Therapeutic (TECX)<\/strong> \u2014 Oppenheimer reiterated its Outperform rating with a US$80.00 price target.<\/p>\n

Tectonic Therapeutic (TECX)<\/strong> \u2014 TD Cowen reiterated its Buy rating.<\/p>\n

TFI International (TFII)<\/strong> \u2014 RBC Capital maintained its Outperform rating and lowered its price target to US$144.00 from US$171.00.<\/p>\n

Third Coast Bancshares (TCBX)<\/strong> \u2014 Brean Capital initiated coverage with a Neutral rating and a US$47.00 price target.<\/p>\n

Transdigm Group (TDG)<\/strong> \u2014 Wells Fargo maintained its Equal Weight rating and lowered its price target to US$1,210.00 from US$1,450.00.<\/p>\n

Tronox (TROX)<\/strong> \u2014 Mizuho maintained its Underperform rating and lowered its price target to US$4.50 from US$5.50.<\/p>\n

Uber Technologies (UBER)<\/strong> \u2014 Bernstein reiterated its Outperform rating.<\/p>\n

UFP Industries (UFPI)<\/strong> \u2014 Oppenheimer initiated coverage with a Perform rating.<\/p>\n

uniQure (QURE)<\/strong> \u2014 Goldman Sachs maintained its Neutral rating and lowered its price target to US$31.00 from US$46.00.<\/p>\n

Vail Resorts (MTN)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and lowered its price target to US$142.00 from US$147.00.<\/p>\n

Vale (VALE)<\/strong> \u2014 JPMorgan Chase maintained its Overweight rating and raised its price target to US$22.00 from US$21.00.<\/p>\n

Viking (VIK)<\/strong> \u2014 UBS reiterated its Buy rating.<\/p>\n

Wayfair (W)<\/strong> \u2014 Piper Sandler reiterated its Overweight rating with a US$133.00 price target.<\/p>\n

Westlake (WLK)<\/strong> \u2014 Citigroup maintained its Neutral rating and lowered its price target to US$67.00 from US$85.00.<\/p>\n

Woodward (WWD)<\/strong> \u2014 Wells Fargo maintained its Overweight rating and lowered its price target to US$430.00 from US$440.00.<\/p>\n

Workday (WDAY)<\/strong> \u2014 Cantor Fitzgerald reiterated its Overweight rating.<\/p>\n

Xencor (XNCR)<\/strong> \u2014 Wells Fargo resumed coverage with an Overweight rating and a US$55.00 price target.<\/p>\n

Zenas BioPharma (ZBIO)<\/strong> \u2014 Citigroup reiterated its Buy rating.<\/p>\n

Zenas BioPharma (ZBIO)<\/strong> \u2014 Guggenheim reiterated its Buy rating with a US$55.00 price target.<\/p>\n

Zenas BioPharma (ZBIO)<\/strong> \u2014 H.C. Wainwright reiterated its Buy rating with a US$44.00 price target.<\/p>\n

Zenas BioPharma (ZBIO)<\/strong> \u2014 Wedbush reiterated its Outperform rating with a US$45.00 price target.<\/p>\n

Zentalis Pharmaceuticals (ZNTL)<\/strong> \u2014 Wells Fargo resumed coverage with an Equal Weight rating and a US$5.00 price target.<\/p>\n

More Ratings:<\/em><\/strong><\/a><\/h3>\n","protected":false},"excerpt":{"rendered":"

Analyst Ratings (USA) Today\u2019s U.S. analyst updates suggest a selective and cautious market outlook, with optimism concentrated in cloud computing, AI infrastructure and networking,…<\/p>\n","protected":false},"author":3,"featured_media":75412,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-75711","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"\nU.S. Analyst Updates: September 30th, 2026 | Stock Target Advisor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"U.S. Analyst Updates: September 30th, 2026\" \/>\n<meta property=\"og:description\" content=\"Analyst Ratings (USA) Today\u2019s U.S. analyst updates suggest a selective and cautious market outlook, with optimism concentrated in cloud computing, AI infrastructure and networking,…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-30T19:41:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-30T19:43:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2026\/09\/canadian-analyst-update.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1213\" \/>\n\t<meta property=\"og:image:height\" content=\"522\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"STA Research\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"STA Research\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"17 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/\"},\"author\":{\"name\":\"STA Research\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\"},\"headline\":\"U.S. Analyst Updates: September 30th, 2026\",\"datePublished\":\"2026-09-30T19:41:46+00:00\",\"dateModified\":\"2026-09-30T19:43:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/\"},\"wordCount\":3769,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News & Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/\",\"name\":\"U.S. Analyst Updates: September 30th, 2026 | Stock Target Advisor\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2026-09-30T19:41:46+00:00\",\"dateModified\":\"2026-09-30T19:43:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"U.S. Analyst Updates: September 30th, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\",\"name\":\"STA Research\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"caption\":\"STA Research\"},\"description\":\"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"U.S. Analyst Updates: September 30th, 2026 | Stock Target Advisor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/","og_locale":"en_US","og_type":"article","og_title":"U.S. Analyst Updates: September 30th, 2026","og_description":"Analyst Ratings (USA) Today\u2019s U.S. analyst updates suggest a selective and cautious market outlook, with optimism concentrated in cloud computing, AI infrastructure and networking,…","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2026-09-30T19:41:46+00:00","article_modified_time":"2026-09-30T19:43:23+00:00","og_image":[{"width":1213,"height":522,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2026\/09\/canadian-analyst-update.png","type":"image\/png"}],"author":"STA Research","twitter_card":"summary_large_image","twitter_creator":"@AdvisorTarget","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"STA Research","Est. reading time":"17 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/"},"author":{"name":"STA Research","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae"},"headline":"U.S. Analyst Updates: September 30th, 2026","datePublished":"2026-09-30T19:41:46+00:00","dateModified":"2026-09-30T19:43:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/"},"wordCount":3769,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News & Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/","name":"U.S. Analyst Updates: September 30th, 2026 | Stock Target Advisor","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2026-09-30T19:41:46+00:00","dateModified":"2026-09-30T19:43:23+00:00","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-september-30th-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"U.S. Analyst Updates: September 30th, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae","name":"STA Research","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","caption":"STA Research"},"description":"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.","url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/75711","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=75711"}],"version-history":[{"count":5,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/75711\/revisions"}],"predecessor-version":[{"id":75726,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/75711\/revisions\/75726"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/75412"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=75711"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=75711"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=75711"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}